ABSTRACT:
Aims: To investigate in-silico result of potent phytocomponent amphimedine against Alzheimer’s disease as Glycogen synthase kinase-3 inhibitor. Background: The neurodegenerative illnesses Parkinson's disease (PD) and Alzheimer's disease (AD) have become two of the most significant health issues of the twenty-first century. The drugs currently used to treat AD and PD are ineffective and have side effects. One of the most important and conservative sources of medications for treating neurological issues is natural goods.
Objective: A Pyrido-acridines congener is amphimedine. However, a thorough investigation into amphimedine's impact on AD has yet to be conducted. Numerous in silico investigations, beginning with molecular docking against glycogen synthase kinase-3 for AD, were performed to assess the neuroprotective impact of amphimedine. Utilizing the software Auto Dock 4.1, the results were contrasted with those of three conventional medications. Amphimedine's physiochemical characteristics, including the Lipinski rule of five, drug-likeness, and factors like its absorption, distribution, metabolism, elimination, and toxicity (ADMET) profiles, were also investigated. With acceptable ADMET profiles for therapeutic usage, Amphimedine conforms to all five of Lipinski's parameter. Method: Autodock tools carried out the docking investigation. On the RCSB website, the necessary proteins have been downloaded. The ProTox-II service projected its toxicity category.
Result: The phytocompound has strong affinityfor 1Q5K as GSK-3 blocker. The molecule's toxicology has been examined. As a result, we now recognize that this scaffold solely exhibits immunotoxicity and falls into toxicity class 4. Conclusion: In comparison to currently prescribed standard medications, the docking results (kcal/mol) demonstrated relatively better effectiveness against AD-related targets. Overall, molecular docking's potential binding affinity and additional multiparametric drug-ability profiles imply that amphimedine might be a good therapeutic lead for treating AD. However, employing amphimedine as a prospective medicine against AD treatment requires more clinical and in vivo investigations, where the in-silico data are more beneficial to speed up drug design.
Cite this article:
Dipanjan Karati. In-Silico Investigational Study of Pyrido-acridine Congener Amphimedine against Alzheimer’s Disease. Asian Journal of Pharmaceutical Research.2025; 15(4):364-8. doi: 10.52711/2231-5691.2025.00056
Cite(Electronic):
Dipanjan Karati. In-Silico Investigational Study of Pyrido-acridine Congener Amphimedine against Alzheimer’s Disease. Asian Journal of Pharmaceutical Research.2025; 15(4):364-8. doi: 10.52711/2231-5691.2025.00056 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-4-2
6. REFERENCE:
1. Saini NK, Mankoo N, Bhandari DD. An Inspiration to Modern Medicines: A Review. Research Journal of Pharmacognosy and Phytochemistry. 2024; 16(2): 121-4.
2. Pahari N, Majumdar S, Karati D, Mazumder R. Exploring the pharmacognostic properties and pharmacological activities of phytocompounds present in Ficus racemosalinn.: A concise review, Pharmacological Research - Modern Chinese Medicine. 2022; 4: 100137.
3. Mukherjee S, Karati D. A Mechanistic View on Phytochemistry, Pharmacognostic Properties, and Pharmacological Activities of Phytocompounds Present in Zingiber officinale: A Comprehensive Review, Pharmacological Research - Modern Chinese Medicine. 2022 https://doi.org/10.1016/j.prmcm.2022.100173.
4. Banerjee J, Karati D. In-silico pharmacology against cancer of a novel phytosterol Dendrosterone isolated from plant Dendrobium ochreatum, Pharmacological Research- Modern Chinese Medicine. 2022. DOI: https://doi.org/10.1016/j.prmcm.2022.100149.
5. Banerjee J, Karati D. Isolation, characterizations, and antimicrobial activities of a phytosterol Dendrosterone isolated from plant Dendrobium ochreatum, Pharmacological Research- Modern Chinese Medicine. 2022; 3: 100120.
6. Patel Dk, Therapeutic effectiveness of Magnolin on cancers and other human complications, Pharmacological Research - Modern Chinese Medicine. 2023; 6: 100203.
7. Blennow K, Leon MJD, Zetterberg H, Alzheimer's disease, Lancet. 2006; 368-387.
8. Joshi R. A Study to assess effectiveness of Structured Teaching Programme on Knowledge regarding Alzheimer diseases among Geriatric peoples in selected old age home in Mehsana. Int. J. Nur. Edu. and Research. 2020; 8(2): 202-204.
9. Buchake VV, Muthal AP, Saudagar RB, Bachhav RS. A Neurodegenerative disorder-Alzheimer disease: A Treatise. Research J. Pharmacology and Pharmacodynamics. 2010; 2(4): 268-273.
10. K. Periyanayagam, Gokila. S, K.G. Balasubramaniam, P.A.T. Jagatheeswary, J. Suriakumar, R. Parameshwari. Protective Effect of the Leaves of Solanum torvums wartz on Drosophila melanogaster against β-Amyloid Induced Alzheimer Disease. Research J. Pharm. and Tech. 2015; 8(6): 719-727.
11. Syaban MFR, Muhammad RF, Adnani B, Putra GFA, Erwan NE et al., Molecular Docking Studies of Interaction Curcumin against Beta-secretase 1, Amyloid A4 Protein, Gamma-secretase and Glycogen Synthase Kinase-3β as Target Therapy for Alzheimer Disease. Research Journal of Pharmacy and Technology. 2022; 15(7): 3069-4.
12. Sayas CL, Ávila J, GSK-3 and Tau: A Key Duet in Alzheimer’s Disease, Cells. 2021; 10: 721.
13. Avila J, Lucas JJ, Pérez M, Hernández F. Role of Tau Protein in Both Physiological and Pathological Conditions. Physiol. Rev. 2004; 84: 361–384.
14. Hernánde, F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: A possible link between beta amyloid peptide and tau protein. Exp. Neurol. 2010; 223: 322–325.
15. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S et al., Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 2008; 172: 786–798.
16. Takashima A, Noguchi K, Michel G, Mercke, M, Hoshi M et al., Exposure of rat hippocampal neurons to amyloid beta peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 1996; 203: 33–36.
17. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J. Alzheimer’s Dis. 2006; 9: 309–317.
18. Cai Z, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer’s disease. Curr. Alzheimer Res. 2012; 9: 864–879.
19. Uemura K, Kuzuya A, Shimozono Y, Aoyagi N, Ando K, Shimoham, S, Kinoshita A. GSK3beta activity modifies the localization and function of presenilin 1. J. Biol. Chem. 2007; 282: 15823–15832.
20. Mines MA, Beurel E, Jope RS. Regulation of cell survival mechanisms in Alzheimer’s disease by glycogen synthase kinase-3. Int. J. Alzheimer’s Dis. 2011; 861072.
21. Pal D, Mukherjee S, Song IH, Nimse SB. GSK-3 Inhibitors: A new class of drugs for Alzheimer’s Disease Treatment. Current Drug Targets. 2021 Nov 1; 22(15):1725-37.
22. Longley RE, McConnell OJ, Essich E, Harmody D. Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity. J. Nat. Prod. 1993; 56: 915-920.
23. Sharma V, Sharma PC, Kumar V. In Silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents Hindawi Advances in Chemistry, 2016.
24. Nurhayati APD, Lianingsih F, Indiani AM, Ghaissani SS, In Silico Study of Natural Pyridoacridine against CDK-2 and CDK-6 Cancer, Eco. Env. and Cons. 2021; 27: S25-S30.
25. Joule JA, Álvarez M, Pyridoacridines in the 21st Century, European Journal of Organic Chemistry, 10.1002/ejoc.201900401.
26. Otuokere IE, Amaku FJ, Alisa CO. In Silico Geometry Optimization, Excited – State Properties of (2E)-N-Hydroxy-3-[3-(Phenylsulfamoyl) Phenyl] prop-2-Enamide (Belinostat) and its Molecular Docking Studies with Ebola Virus Glycoprotein. Asian J. Pharm. Res. 2015; 5(3): 131-137.
27. Nandhini S, Radha R , Vadivu R. Docking of Hematoporphyrin on Various Anticancer Drugs Targeting Enzymes. Asian J. Pharm. Res. 2016; 6(3): 123-130.
28. Patadiya N, Vaghela V. Design, in-silico ADME Study and molecular docking study of novel quinoline-4-on derivatives as Factor Xa Inhibitor as Potential anti-coagulating agents. Asian Journal of Pharmaceutical Research. 2022; 12(3):207-1.
29. Pawar S, Kulkarni C, Gadade P, Pujari S, Kakade S et al., Molecular Docking using different Tools. Asian Journal of Pharmaceutical Research. 2023; 13(4): 292-6.
30. Sindhu TJ, Arathi KN, Devi A, Aswathi TA, Noushida M, Midhun M et al., Synthesis, Molecular Docking and Antibacterial Studies of Novel Azole derivatives as Enoyl ACP Reductase Inhibitor in Escherichia coli. Asian J. Res. Pharm. Sci. 2019; 9(3): 174-180.
31. Vardhan DMS, Kumara HK, Kumar HP, Gowda DC. Urea and Thiourea Derivatives of Dipeptides Conjugated Piperazine Analogue as A New Class of AGE’s Inhibitors: Synthesis and Molecular Docking Studies. Asian J. Research Chem. 2017; 10(4): 459-469.
32. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018; 46: W257–W263.